Genmab, Kyowa Hakko Kirin deal

Genmab will use its DuoBody technology to create bispecific antibodies against an undisclosed target from Kyowa. Genmab said the deal includes an option to license rights to a DuoBody product. Genmab will receive an undisclosed upfront payment, plus research funding. Genmab declined to disclose details, and Kyowa could not be reached. ...